Big gain for Allakos as first-in-class GI program heads toward pivotal phase

Allakos' management team has plenty of experience in M&A, and a new Phase II readout in eosinophilic GI disorders could provoke interest in the company as a Phase III-ready bolt-on acquisition target.

Allakos Inc. (NASDAQ:ALLK) more than doubled in value Monday after reporting that its first-in-class program targeting sialic acid binding Ig like lectin

Read the full 532 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers